• Skip to primary navigation
  • Skip to main content

National Forum

  • Home
  • About
    • Advisory Leadership Council
    • Board of Directors
    • 2021-22 Strategic Plan
    • History
    • National Forum Awards
    • Team
    • Support
    • Careers
  • Collaborations
    • Awareness Months 2023
    • Counter Cholesterol™
    • Flu Prevention
    • Know Your Numbers
    • Million Hearts®
      • Million Hearts® Stakeholders Flu Vaccination Campaign ’22
    • Move with the Mayor™
    • Signature Reports
    • Stronger Hearts™
    • Value & Access
    • Value & Innovation Forum
  • Events
    • National Forum and Member Events
    • Health Equity Benefits Everyone – January 2023
    • 2022 Annual Meeting
    • 2022 Mid-Year Virtual Convening
    • 2021 Annual Meeting
    • 2021 Mid-Year Virtual Convening
    • Heart Failure Roundtable
    • Value & Innovation Forum
    • Meeting Archives
      • 2020 Annual Meeting
      • 2020 Mid-Year Meeting
      • 2019 Annual Meeting
      • 2019 Virtual Convening on Stroke
      • 2019 Mid-Year Member Meeting
      • 2018 Annual Meeting
      • 2018 Mid Year Meeting
  • Members
    • Membership
  • Newsroom
  • Search Toggle
  • Skip to content

National Forum Statement on Praluent Price Change

Posted on 03.13.19

The National Forum issued the following statement in response to Sanofi and Regeneron’s announcement that they cut the list price of their LDL (“bad”) cholesterol-lowering treatment, Praluent, to $5,850 annually, a 60 percent reduction from the original list price. Amgen announced a similar price reduction in October 2018 on Repatha. Both Praluent and Repatha are PCSK9 inhibitors, a new class of drugs that lower LDL cholesterol in people for whom other treatments are not sufficient.

Leaders representing patients, providers, payers, purchasers, public health and pharma/biotech have joined forces through the National Forum Value & Access Initiative to enhance health and well-being by supporting people’s access to evidence-based care that is appropriate for them. The foremost strategy recommended by this group is to support the implementation of evidence-based care that aligns incentives for all stakeholders.

The price change announced by Sanofi and Regeneron appears to support the Value & Access Steering Committee’s consensus strategy to align incentives. Patients, providers, public health and those who pay the bills for healthcare could benefit from this price reduction if it leads to easier access to the drug for appropriate patients.

Over 39 million Americans who have high LDL cholesterol that puts them at high risk of a heart attack or stroke are not taking medications to control their cholesterol[1]. Most could be successfully treated with a statin. However, some patients have been shown to need a PCSK9 inhibitor, such as Praluent and Repatha.

There are multiple stakeholders whose decisions and actions affect patients’ access and out-of-pocket costs for drug therapy, such as manufacturers, health plans, pharmacy benefit managers, and healthcare providers. The National Forum and its members hope the recent price reductions for Praluent and Repatha will result in improved access and affordability for appropriate patients, as indicated by the 2018 ACC/AHA Multisociety Cholesterol Treatment Guidelines.

[1] Million Hearts: Cholesterol Management, accessed 3/7/19 at https://millionhearts.hhs.gov/tools-protocols/tools/cholesterol-management.html

Categories: In the News, Value & Access

1150 Connecticut Ave., NW, Suite 300, Washington, DC 20036 Phone: (866) 894-3500
Copyright © 2023 National Forum for Heart Disease & Stroke Prevention. All Rights Reserved
  • Facebook
  • Twitter
  • YouTube
Contact

"*" indicates required fields

Name * Required
This field is for validation purposes and should be left unchanged.